MK-677 (Ibutamoren) Evidence Base Graded by GRADE

The direct answer

MK-677 (ibutamoren) consistently raises growth hormone and IGF-1 in every completed placebo-controlled human trial reviewed here, and that effect is graded Moderate confidence under GRADE. Bone mineral density improvements over 12 to 24 months are also graded Moderate, but no trial has ever measured fracture incidence. Body composition changes, sleep architecture effects, and cognitive effects are graded Low to Very Low because the trials behind them are small, short, or not designed to detect those outcomes reliably. The drug has no FDA-approved indication, and long-term cardiovascular and safety data beyond 24 months do not exist.

What MK-677 is and how it works

MK-677 is the research code name; ibutamoren is the generic (INN) name. It has no FDA-approved brand name because it is not an approved drug. It belongs to the growth hormone secretagogue class and works by activating GHS-R1a, the ghrelin receptor, on pituitary somatotrophs and hypothalamic neurons. This produces a sustained increase in pulsatile GH secretion without the direct exogenous GH delivery that recombinant human growth hormone (rhGH) provides. Because it acts upstream of GH release rather than replacing GH itself, the body's own feedback loops on the GH axis remain structurally intact, which is mechanistically distinct from rhGH.

Unlike injectable peptide secretagogues (GHRP-2, GHRP-6, sermorelin), MK-677 is orally bioavailable, with a plasma half-life in the range of several hours, supporting once-daily dosing in the trials reviewed below.

GRADE framework applied to MK-677 research

GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) scores evidence across risk of bias, inconsistency, indirectness, and imprecision. Randomized trial evidence starts at High confidence and is downgraded for weaknesses in these domains. The Cochrane Handbook defines the criteria applied here. (Cochrane Handbook, version 6.4)

GH and IGF-1 elevation: GRADE Moderate

Every published placebo-controlled trial in this review reports statistically significant GH and IGF-1 increases at oral doses of 10 mg to 25 mg daily. The direction and statistical significance of this effect are not in dispute. The Moderate rating, rather than High, reflects short follow-up in most trials and enrollment skewed toward healthy volunteers rather than the populations who might actually use the drug clinically.

Murphy 1998: a frequently cited but incompletely verifiable trial

An early small trial is commonly cited as an early demonstration of MK-677's GH and IGF-1 effects in adults, though a matching, verifiable primary source could not be confirmed and is not cited here. No specific percentage from that trial should be treated as confirmed.

Dose-response across populations

A small trial reportedly tested 10 mg and 25 mg doses of MK-677 in 24 healthy young men. The 25 mg arm reportedly produced a larger increase in integrated overnight GH than the 10 mg arm, suggesting a dose-response relationship, and both doses reportedly raised IGF-1 within about a week.

A separate small trial in adults with confirmed GH deficiency reportedly found that ibutamoren at 10 to 25 mg raised IGF-1 into the normal reference range in subjects with documented somatotroph insufficiency, suggesting that the mechanism functions even under a pathological GH axis.

Body composition: GRADE Low

Short-term lean-mass and fat-mass signals appear real, but they become inconsistent with longer follow-up. The Low rating reflects that inconsistency, plus the fact that the longest trial (Nass 2008) did not show a durable lean-mass benefit.

Short-term changes

A small trial reportedly found roughly a 2.0 kg increase in lean body mass and a 2.7 kg decrease in fat mass after 8 weeks of MK-677 25 mg in obese but otherwise healthy men. For context, that magnitude is broadly comparable to what low-dose rhGH produces over roughly three months, though the two interventions have not been compared head to head.

What happened at 12 and 24 months

A frequently cited two-year, double-blind trial reportedly examined MK-677 25 mg daily in 65 adults aged 60 to 81. Fat mass reportedly fell at 6 months but drifted back toward baseline by 12 months. Lean mass reportedly increased modestly at 12 months, but the effect was no longer statistically distinguishable from no effect at 24 months. The authors attributed this attenuation partly to compensatory downregulation of the IGF-1 response over time.

Hip fracture recovery sub-study

A small randomized trial reportedly assigned 123 older adults recovering from hip fracture to MK-677 25 mg or placebo for 6 months. MK-677 reportedly improved functional reach and chair-stand performance compared with placebo, but the lean-mass difference at 6 months lost statistical significance after adjustment for baseline variability. The functional signal is worth noting; the body composition signal did not meet the trial's pre-specified threshold.

Bone mineral density: GRADE Moderate

Bone density findings are the most internally consistent result in this literature after the GH/IGF-1 endpoint itself. A small number of trials report significant BMD increases at the lumbar spine and femoral neck after 12 to 24 months.

In that same long-term cohort, lumbar spine BMD reportedly increased in the MK-677 arm while it declined in the placebo arm over 12 months, with a similar pattern reported at the femoral neck. These are modest, directionally consistent changes plausibly linked to anabolic GH/IGF-1 effects on osteoblast activity.

No published RCT has used fracture incidence as a primary or secondary endpoint. That absence is the specific reason this evidence is not rated higher than Moderate. The Endocrine Society's clinical practice guideline on adult GH deficiency makes the general point that surrogate measures such as BMD do not reliably predict fracture reduction without prospective fracture data to confirm it. (Endocrine Society CPG, JCEM 2011)

Sleep architecture: GRADE Low

Two small, well-designed crossover studies report increases in slow-wave sleep (SWS) and changes in REM sleep timing during MK-677 administration. Both are single-site, short-duration trials with fewer than 30 participants.

A small crossover study reportedly examined 24-hour sleep-wake cycles in healthy young men taking MK-677 10 mg or 25 mg for 14 days and found an increase in SWS and a shortened REM latency in the higher-dose arm, with GH pulse amplitude reportedly correlating with SWS duration.

SWS is a surrogate endpoint for sleep quality. No MK-677 trial has used validated patient-reported sleep instruments, such as the Pittsburgh Sleep Quality Index or Epworth Sleepiness Scale, as a primary outcome. The Low rating reflects single-site replication, small sample size, and reliance on a surrogate measure rather than a patient-centered outcome.

Cognitive function: GRADE Very Low

Two trials have examined MK-677 in relation to cognition, both in elderly subjects, and neither was designed with cognition as its primary outcome.

In that same two-year trial, a pre-specified cognitive sub-analysis reportedly used the Digit Symbol Substitution Test (DSST) and Trail Making Test B. DSST scores reportedly declined less in the MK-677 arm than in placebo over 24 months, but the difference did not reach statistical significance, and the study was reportedly not powered to detect cognitive effects.

GRADE Very Low means confidence in the effect estimate is low enough that the true effect could be substantially different from what was measured. Here that reflects indirect endpoints used as a proxy for meaningful cognitive change, a high dropout rate over 24 months, and a post-hoc subgroup design. No completed or registered Phase III cognition trial of ibutamoren exists as of mid-2025.

Safety and adverse effects: GRADE Moderate for the metabolic signal

Adverse events were measured more consistently across trials than most efficacy outcomes, so the safety picture is, in some respects, better characterized than the efficacy picture.

Insulin resistance and glucose metabolism

GH is inherently insulin-antagonizing. That same long-term trial reportedly found a statistically significant rise in fasting insulin and an increase in HOMA-IR at 12 months in the MK-677 arm, with two subjects in that arm developing new-onset fasting glucose values that met the ADA diagnostic threshold for diabetes. (ADA Standards of Medical Care in Diabetes 2024) Anyone considering ibutamoren with a clinician should expect baseline HbA1c and fasting glucose to be part of that conversation, particularly with pre-existing prediabetes.

Fluid retention and edema

Peripheral edema was reported more often in MK-677 arms than placebo arms across the trials reviewed here. The proposed mechanism is GH-mediated sodium and water reabsorption at the distal tubule. Reported edema generally resolved within a few weeks of dose reduction or discontinuation.

Increased appetite and cortisol

Because MK-677 mimics ghrelin, appetite stimulation is an expected and consistently observed effect; the Copinschi trial recorded larger increases in subjective hunger scores in the treatment arm than in placebo. Morning cortisol reportedly rose modestly in one early trial's 25 mg arm, while 24-hour cortisol exposure was reportedly unchanged, suggesting a shift in timing rather than sustained hypercortisolism; as above, this specific trial could not be verified against a matching source and is not cited here.

Regulatory status and the long-term safety gap

MK-677 was investigated under an Investigational New Drug application by Merck and later other sponsors. No New Drug Application was ever filed or approved, and it is not a legally marketed prescription drug in the United States as of 2025. Compounded or research-grade ibutamoren sold outside that framework falls under the FDA's general guidance on unapproved and compounded drug products. (FDA, Compounding and the FDA: Q&A) No published trial has followed subjects for longer than 24 months, so cardiovascular and other long-term outcomes over years of use are simply unknown rather than reassuring.

What is established, what is plausible, and what is not established

Established from RCT evidence: oral MK-677 at 10 to 25 mg raises GH and IGF-1 reliably in the short term; it raises fasting insulin and HOMA-IR consistently; and it increases the rate of peripheral edema and appetite compared with placebo.

Plausible but unproven: that the observed bone density gains translate into fewer fractures; that short-term lean mass or fat mass benefits persist beyond 12 months in most users; that sleep architecture changes translate into better subjective sleep quality; that the drug meaningfully helps functional recovery after injury in older adults, an area where one trial's signal is promising but not confirmed.

Not established: any cognitive benefit; safety or efficacy beyond 24 months; safety or efficacy in women, children, adolescents, or people with an intact GH axis (most trial populations were elderly men or adults with diagnosed GH deficiency); interaction risk with metformin, GLP-1 receptor agonists, or exogenous testosterone, none of which have been formally studied together with ibutamoren; and any FDA-recognized indication.

MK-677 (ibutamoren) is an orally active, non-peptide ghrelin-receptor agonist with no FDA-approved indication as of 2025. In every completed placebo-controlled trial, 10 to 25 mg daily raised GH and IGF-1 (GRADE: Moderate), and a small number of trials found bone density gains over 12 to 24 months (GRADE: Moderate), but no trial has measured fracture, cardiovascular, or mortality outcomes. Effects on lean mass, fat mass, sleep, and cognition are graded Low to Very Low because the underlying trials are small, short, or not designed to answer those questions with confidence.

Evidence gaps that limit clinical translation

No Phase III data. Every MK-677 trial identified here is Phase I or Phase II, with sample sizes in the tens to low hundreds. Development was discontinued before a Phase III program was completed.

Population indirectness. Most trials enrolled healthy elderly volunteers or adults with diagnosed GH deficiency. Athletes, younger adults seeking body composition changes, and people with obesity but a preserved GH axis are essentially unstudied in controlled trials, which is a direct source of GRADE downgrading for indirectness.

Surrogate-only endpoints. IGF-1, BMD, and DSST scores are surrogates, not clinical outcomes. Fracture incidence, quality-adjusted life years, cardiovascular events, and mortality have not been measured in any prospective MK-677 trial. The Endocrine Society's guideline on adult GH deficiency makes a comparable general point about not substituting surrogate normalization for outcome data. (Endocrine Society CPG, JCEM 2011)

Missing pediatric and predominantly female data. No published RCT has enrolled a primarily female cohort or a pediatric population. Sex differences in GH secretory dynamics are well documented in the endocrinology literature, so extrapolating trial results in men to women is not supported by direct evidence.

No formal drug interaction data. No published pharmacokinetic interaction study has examined MK-677 with insulin sensitizers, GLP-1 receptor agonists, or exogenous testosterone, combinations that are common in off-label hormone-optimization settings. Anyone combining these is extrapolating from mechanism, not from data.

A decision framework for reading this evidence base

This framework does not replace individualized medical advice. It maps the graded evidence in this article to common reasons people ask about MK-677, so a reader can see where the evidence base actually supports a conversation with a clinician and where it does not.

Practical takeaways for evaluating the literature

These are evidence-level summaries, not prescribing or dosing instructions. Any individualized decision about ibutamoren belongs in a conversation with a qualified clinician who can weigh a specific person's history, labs, and risk factors.

The GH/IGF-1 response is the best-supported outcome in this literature, at GRADE Moderate. Body composition benefits are real in short trials but attenuate over 12 months. Bone density data are moderately strong but have never been connected to fracture outcomes.

Baseline and follow-up metabolic monitoring is supported by multiple independent trials showing insulin resistance as a consistent pharmacological consequence of GH-axis stimulation. The ADA's 2024 Standards of Care describe general monitoring principles relevant to therapies that induce insulin antagonism. (ADA Standards of Medical Care 2024)

No published safety or efficacy data support doses above 25 mg daily. The Nass 2008 trial, at 25 mg for 24 months, remains the only long-duration controlled study; anything beyond that dose or duration is extrapolation rather than evidence. Anyone with active malignancy, uncontrolled diabetes, significant fluid retention, or heart failure should treat ibutamoren as contraindicated based on trial exclusion criteria and mechanistic risk, and anyone experiencing new swelling, unexplained thirst or urination, or rapid weight change while using it should seek medical evaluation rather than waiting it out.